{"organizations": [], "uuid": "a65f7611c024852ac281d1f8077e5bbbb9929a6b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-loxo-oncology-reports-quarterly-no/brief-loxo-oncology-reports-quarterly-non-gaap-net-loss-per-share-1-24-idUSASB0C88M", "country": "US", "domain_rank": 408, "title": "Loxo Oncology Reports Quarterly Non-Gaap Net Loss Per Share $1.24", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.429, "site_type": "news", "published": "2018-03-01T19:48:00.000+02:00", "replies_count": 0, "uuid": "a65f7611c024852ac281d1f8077e5bbbb9929a6b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-loxo-oncology-reports-quarterly-no/brief-loxo-oncology-reports-quarterly-non-gaap-net-loss-per-share-1-24-idUSASB0C88M", "ord_in_thread": 0, "title": "Loxo Oncology Reports Quarterly Non-Gaap Net Loss Per Share $1.24", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "loxo oncology inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - Loxo Oncology Inc:\n* LOXO ONCOLOGY REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS\n* ‍LAROTRECTINIB ROLLING NDA SUBMISSION ON TRACK FOR COMPLETION IN MARCH​\n* ‍LOXO-292 PHASE 1 CLINICAL DATA UPDATE EXPECTED IN FIRST HALF 2018​\n* ‍ REVENUE FROM COLLABORATION AGREEMENT WAS $21.3 MILLION FOR Q4 COMPARED TO NONE FOR Q4 2016​\n* INITIATION OF PHASE 1 CLINICAL TRIAL FOR LOXO-305 (BTK) IS EXPECTED IN SECOND HALF OF 2018\n* QTRLY NET LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED $0.69‍​\n* QUARTERLY NON-GAAP NET LOSS PER SHARE $1.24\n* Q4 EARNINGS PER SHARE VIEW $-1.13 — THOMSON REUTERS I/B/E/S Source text for Eikon: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T19:48:00.000+02:00", "crawled": "2018-03-02T19:49:38.016+02:00", "highlightTitle": ""}